Adjunctive Steroids Are Not Beneficial in Non–HIV-Associated PCP

In HIV-uninfected patients with moderate-to-severe Pneumocystis jirovecii pneumonia, outcomes were similar between patients who received adjunctive corticosteroids and those who did not.

Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection in immunocompromised patients, including those with HIV infection. Corticosteroids are of proven benefit as adjunctive treatment for PCP in HIV-infected patients and should be given to such individuals within 72 hours after antibiotic initiation if the PaO₂ is ≤70 mm Hg. However, the benefit of adjunctive corticosteroids for non–HIV-associated PCP remains unknown.

To explore this issue, researchers in Korea conducted a retrospective analysis of HIV-uninfected, immunocompromised patients with laboratory-confirmed, moderate-to-severe PCP. Among these 88 patients, 26 were solid organ transplant recipients, 26 (including 5 who had undergone hematopoietic stem cell transpl…

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Adjunctive Steroids Are Not Beneficial in Non–HIV-Associated PCP

Topics

Reviewing Author